UroGen Pharma to Present at Upcoming Investor Conferences
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) announced participation in three investor conferences in May 2026: Bank of America Health Care Conference (May 13, 11:15 AM ET, Las Vegas), HC Wainwright BioConnect (May 19, 10:30 AM ET, New York), and TD Cowen Oncology Innovation Summit (May 26, 10:30 AM ET, virtual).
Webcasts will be available on UroGen’s Investor Relations website and replayed for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – URGN
In the May 7 session, URGN gained 1.30%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.7% during that session. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May.
| Bank of America Health Care Conference 2026 | |
| Date / Time: | May 13th, at 11:15 AM ET |
| Format: | 1x1’s |
| Location: | Las Vegas, NV |
| Webcast Link: | Here |
| HC Wainwright 4th Annual BioConnect Investor Conference | |
| Date / Time: | May 19th, at 10:30 AM ET |
| Format: | 1x1’s |
| Location: | New York, NY |
| Webcast Link: | Here |
| TD Cowen 7th Annual Oncology Innovation Summit | |
| Date / Time: | May 26th, at 10:30 AM ET |
| Location: | Virtual |
| Webcast Link: | Here |
The webcasts from the conference will also be available on UroGen’s Investor Relations website. A replay will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adults with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
